Back to Search Start Over

Trans-acting aptazyme for conditional gene knockdown in eukaryotic cells

Authors :
Shan Zhou
Meiyi Chen
Yi Yuan
Yan Xu
Qinlin Pu
Xilei Ai
Shuai Liu
Feng Du
Xin Huang
Juan Dong
Xin Cui
Zhuo Tang
Source :
Molecular Therapy: Nucleic Acids, Vol 33, Iss , Pp 367-375 (2023)
Publication Year :
2023
Publisher :
Elsevier, 2023.

Abstract

Trans-acting hammerhead ribozyme inherits the advantages of being the smallest and best-characterized RNA-cleaving ribozyme, offering high modularity and the ability to cleave any desired sequence without the aid of any protein, as long as the target sequence contains a cleavage site. However, achieving precise control over the trans-acting hammerhead ribozyme would enable safer and more accurate regulation of gene expression. Herein, we described an intracellular selection of hammerhead aptazyme that contains a theophylline aptamer on stem II based on toxin protein IbsC. Based on the intracellular selection, we obtained three new cis-acting hammerhead aptazymes. Moreover, the corresponding trans-acting aptazymes could be efficiently induced by theophylline to knock down different targeted genes in eukaryotic cells. Notably, the best one, T195, exhibited a ligand-dependent and dose-dependent response to theophylline, and the cleavage efficiency could be enhanced by incorporating multiplex aptazymes.

Details

Language :
English
ISSN :
21622531
Volume :
33
Issue :
367-375
Database :
Directory of Open Access Journals
Journal :
Molecular Therapy: Nucleic Acids
Publication Type :
Academic Journal
Accession number :
edsdoj.49fd6d324f714b53a66d4ff6e1fef7a9
Document Type :
article
Full Text :
https://doi.org/10.1016/j.omtn.2023.07.014